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Background: Computer-aided drug design (CADD) often involves virtual screening (VS) of large compound
datasets and the availability of such is vital for drug discovery protocols. We present CamMedNP - a new database
beginning with more than 2,500 compounds of natural origin, along with some of their derivatives which were
obtained through hemisynthesis. These are pure compounds which have been previously isolated and
characterized using modern spectroscopic methods and published by several research teams spread across
Cameroon.
Description: In the present study, 224 distinct medicinal plant species belonging to 55 plant families from the
Cameroonian flora have been considered. About 80 % of these have been previously published and/or referenced
in internationally recognized journals. For each compound, the optimized 3D structure, drug-like properties, plant
source, collection site and currently known biological activities are given, as well as literature references. We have
evaluated the “drug-likeness” of this database using Lipinski’s “Rule of Five”. A diversity analysis has been carried out
in comparison with the ChemBridge diverse database.
Conclusion: CamMedNP could be highly useful for database screening and natural product lead generation
programs.
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For more than 4 millennia, plants have been used as a
source of medication. According to the World Health
Organization (WHO), phytomedicine is a part of health
care systems around the world [1], and its importance is
underscored by the fact that by 1990 about 80% of drugs
were either natural products (NPs) or analogues inspired
by them [2-4]. Moreover, large proportions of natural
products are biologically active and have favourable
ADME/T (absorption, distribution, metabolism, excre-
tion, and toxicology) properties, despite the fact that* Correspondence: ntiekfidele@gmail.com
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reproduction in any medium, provided the orthey often do not satisfy proposed “drug-likeness” cri-
teria [5]. Thus, modern drug discovery programs often
resort to natural sources to guide the careful design of
“drug-like” leads from suitable scaffolds, often by synthetic
modifications of the latter [6,7]. Nowadays, employing
computer-aided drug design (CADD) methods, which
often incorporate the virtual screening (VS) of large com-
pound databases against validated drug targets followed
by the careful selection of virtual hit compounds to be
screened by biological assays, has become a very import-
ant part of the drug discovery process. This strategy con-
siderably narrows down the number of compounds that
undergo biological screening and hence drastically cuts
down the cost of discovery of a drug [7-10]. The adoption
of this drug discovery strategy has therefore necessitated
the development of databases of virtual compounds. Inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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compound suppliers [11], the past decade has seen the de-
velopment and publication of a number of NP compound
databases: The SuperNatural database [12]; The Chinese
traditional medicinal herbs database [13]; Marine natural
products databases [14,15]; The NAPROC-13 database
[16]; a database for the predicted pharmacophoric features
of medicinal compounds isolated from medicinal plants in
India [17,18]; and the PHARM database, based on Thai
medicinal plants [19].
The fact that the African flora, and the Congo Basin in
particular, holds enormous potential as a source of drugs
for its poverty-stricken populations and the world at
large cannot be overemphasized [20-22]. Located in the
Congo Basin, Cameroon has a rich rain forest and most
of her rural populations have depended on medicinal
plants for the treatment of a number of tropical diseases
until now [21,22]. Interest in these plants led to the cre-
ation of the Department of Organic Chemistry at the
University of Yaoundé (now Yaoundé I, UY), whose NP
research groups have been thereafter actively involved in
the isolation and characterization of active principles
from medicinal plants that could serve as drug leads.
Moreover the research teams born in UY have served as
the nursery for the training of more than 90% of the
current leaders of the various NP research groups spread
throughout the country. For more than four decades,
Cameroonian research groups have been actively involved
in the extraction, purification and characterization of
biologically active compounds from medicinal plants. The
result has been the steady increase in the volume of scien-
tific publications annually. It must, however, be noted that
only the most promising compounds are usually published
in internationally recognized peer reviewed journals. The
seemingly uninteresting ones are only reported in local
journals as well as in MSc and PhD theses. The locally
published and unpublished data, nevertheless, constitute
an enormous wealth of knowledge that has remained un-
available to the wider scientific community. To the best of
our knowledge, a searchable 3D compound database of
pure compounds from Cameroonian medicinal plants has
not been previously reported. Even though the chemical
structures of about 80% of the compounds in CamMedNP
are published in journal articles, the presence of 3D struc-
tures makes the present database valuable for molecular
modelling groups carrying out VS and CADD. Moreover,
little effort has been made locally to develop the expertise
(in areas such as medicinal chemistry), which is required
to mount credible drug development efforts [23]. It is
therefore of value to present a comprehensive data review,
based on the published and unpublished results of the
various research groups. The goal has been to prepare a
database containing 3D structures as well as the physico-
chemical properties, geographical distribution of the plantspecies and the known biological activities of these com-
pounds. In this paper, we present CamMedNP, a new data-
base of 3D chemical structures, available in several file
formats (.mdb, .ldb, .mol2, .sdf), which are readable using
several drug discovery software tools. Thus, CamMedNP
could be used by research groups involved in CADD to
carry out protein-ligand docking, pharmacophore mining,
substructure searching and VS against validated drug tar-
gets. Since these plants have been used traditionally in the
treatment of several medical disorders, the aim of VS
would be to identify suitable compound scaffolds which
could be subjected to further investigation in the search
for lead compounds for the treatment of these and other
diseases. An assessment of the “drug-likeness” of the
CamMedNP database in comparison with the Dictionary
of Natural Products (DNP) is also reported here, as well as




The plant sources, geographical collection sites, chem-
ical structures of pure compounds as well as their spec-
troscopic data, were retrieved from literature sources
comprising of 25 PhD and Habilitation theses from the
libraries of the University of Yaoundé I (UY), University
of Douala (UD), University of Dschang (UDs) and the
University of Buea (UB), all in Cameroon. International
peer reviewed journal sources include 48 journals, with
references ranging from 1982 to 2012. This constitutes a
total of 364 journal references, as well as 4 unpublished
conference presentations (from personal communication
with the authors). The full list of journals consulted is
given in the supplementary material (Additional file 1).
Generation of 3D Models, Optimization and Calculation of
Molecular Descriptors
Based on the known chemical structures of the NPs, all
3D molecular structures were generated using the graph-
ical user interface (GUI) of the MOE software [24] run-
ning on a Linux workstation with a 3.5GHz Intel Core2
Duo processor. The 3D structures were generated using
the builder module of MOE and energy minimization was
subsequently carried out using the MMFF94 force field
[25] until a gradient of 0.01 kcal/mol was reached. The 3D
structures of the compounds were then saved as .mol2
files subsequently included into a MOE database (.mdb)
file and converted to other file formats (.sdf, .mol, .mol2
and .ldb), which are suitable for use in several virtual
screening workflow protocols. The molar weight (MW),
number of rotatable bonds (NRB), lipophilicity parameter
(log P), number of hydrogen bond acceptors (HBA), num-
ber of hydrogen bond donors (HBD), number of Lipinski
violations, total polar surface area (TPSA), number of
Figure 1 Pie chart showing the classification of compound
types currently within the CamMedNP database.
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chiral centres (NCC), and number of rings (NR) were cal-
culated using the molecular descriptor calculator included
in the QuSAR module of the MOE package [24]. The
ChemBridge Diverset database (48,651 compounds) was
downloaded from the official ChemBridge webpage [26].
It is noteworthy that the provided 3D structures are those
published in the literature, based on NMR and other spec-
troscopic techniques. Standard software programs which
implement typical virtual screening workflows usually in-
volve a preliminary treatment of input ligand structures
by tautomer generation and correct protonation at physio-
logical pH. It is the user’s responsibility to implement this
preliminary step during the virtual screening protocol.
Plant families and their chemo-taxonomic classification
Our initial collection gave 2,434 naturally occurring
compounds, alongside 147 products of hemisynthesis
and enzymatic biotransformations of the NPs. The NPs
had been previously isolated from 224 plant species from
55 plant families. However, since the same compound
can be isolated from several plant species, the removal
of duplicates resulted in a total of 1,859 NPs and their
derivatives, among which 33.8% have been derived from
Cameroonian medicinal plants for the very first time.
Duplicates were defined as compounds which have been
reported from more than one species, more than one
family or from the same species, but with different lit-
erature sources. Our analyses have shown that a plurality
(solely based numbers, not relative concentrations) of
the NPs currently included is made of terpenoids, consti-
tuting 28.4%. This is followed respectively by flavonoids
(17.2%), alkaloids (12.8%), xanthones (5.7%), glycosides
(5.4%) and quinones (5.0%), Figure 1. A classification of the
molecules by plant family of origin showed that the most
abundant molecules have been isolated from plants of the
Leguminosae family (15.6%), followed by the Guttiferae
(12.3%), Rutaceae (8.4%), Moraceae (5.5%), Euphorbiaceae
(5.4%), Compositae (5.2%), Bignioniaceae (4.3%) and
Zingiberaceae (4.3%) families respectively (Figure 2A). A
chemo-taxonomic study of the compounds from the
Cameroonian rainforest, currently included within this
database reveals that plants of the Leguminosae family
(Crotalaria sp., Eriosema sp., Erythrina sp., Guibourtia sp.
and Millettia sp.) are particularly rich in flavonoids (consti-
tuting 75.6% of all compounds that have been isolated from
this family), Figure 2B. On the other hand, it was observed
that extracts from the Guttiferae family (Allanblackia sp.,
Calophyllum sp., Endodesmia sp., Garcinia sp., Harungana
sp., Hypericum sp., Pentadesma sp., Psorospermum sp.,
Symphonia sp. and Vismia sp.) are mostly composed of
xanthones (36.5%), and quinones (28.4%), while those
from the Rutaceae family (Afraegle sp., Araliopsis sp.,
Basalmocitrus sp., Clausena sp., Fagara sp., Oricia sp.,Oriciopsis sp., Teclea sp., Vepris sp., and Zanthoxylum
sp.) are rich in alkaloids (53.3 %). Additionally, compounds
isolated from plants of the Moraceae (Dorstenia sp., Ficus
sp., Morus sp., and Trilepisium sp.) were mostly flavonoids
(50.0%); meanwhile plants of the Euphorbiaceae family
(Alchornea sp., Croton sp., Discoglypremna sp., Drypetes
sp., Fontainea sp., Macaranga sp., Maesobotrya sp.,
Neoboutonia sp., and Uapaca sp.) are shown to be rich in
terpenoids (69.5%). The same trend was seen among plants
of the Cecropiaceae family (not shown in Figure 2B). It
was also observed that plants from the Compositae family
(Chromoleana sp., Crassocephalum sp., Crepis sp., Echinops
sp., Elephantopus sp., Helichrysum sp., Microglossa sp., Se-
necio sp., and Tithonia sp.) were mostly rich in terpenoids
(57.0%) while plants from the Bignioniaceae (Kigelia sp.,
Newbouldia sp., Spathodea sp. and Stereospermum sp.) and
Zingiberaceae (Aframomum sp. and Renealmia sp.) families
were respectively rich in quinones (26.3%) and terpenoids
(67.5%). In Figure 2A, plant families with less than 2% iso-
lated compounds have been left out of the discussion for
the sake of clarity.
Secondary metabolites isolated and their known
biological activities
The reported biological activities of CamMedNP have
also been included in our database. From our study, it
was observed that even though the biological activities
of 54.9% of the compounds have not been determined,
the remaining compounds show a wide range of
reported activities. Among the known biological ac-
tivities are unspecific classifications like antimalarial,
antileishmanial, antitubercular, antitrypanosomal, anti-
HIV, antiinflamatory and analgesic, antioxidant, free
radical scavenging, antiproliferative, cytotoxicity, erythro-
cyte susceptibility, spasmogenic, antidiabetic, herbicidal,
Figure 2 Chemical composition by plant family of origin. (A) Bar chart showing the % counts of compounds currently within the CamMedNP
database, classified by plant family of origin. (B) Distribution of compound types within the most abundant plant families currently in CamMedNP.
Each plant family is represented by the first 4 letters of its name (e.g., Bign = Bignioniaceae, . . .). Codes for compound types, represented in
Figure 1, are given by the first 3 letters (e.g., Alk = Alkaloid, . . .).
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http://www.biomedcentral.com/1472-6882/13/88hepatoprotective, cardiovascular, immunoinhibition, im-
munomodulatory, antisalmonellal, vasodilator, vasorelaxant
and hypertensive effects and activity against Onchocerca
gutturosa, while very specific descriptions like inhibition or
modulation of known drug targets include: α-glucosidase
inhibition, butyrylcholinesterase inhibition, urease inhib-
ition, inhibition of phosphodiesterase I and xanthine oxi-
dase, monoamine oxidase inhibition, prolyl endopeptidaseand thrombin inhibition, antitumor, 11β-hydroxysteroid
dehydrogenase inhibition, cholinesterase inhibition, prolyl
endopeptidase I inhibition, inhibition of neuraminidases
from Clostridium perfringens and Vibrio cholerae, snake
venom phosphodiesterase I inhibition, inhibition of
Phospholipase C, β-D-glucosidase, β-glucuronidase and
α-D-Mannosidase inhibition, etc., cytotoxicity against
Mucor miehei and Artemia salina, algicidal activity
Figure 3 Graph distribution of features that determine “drug-likeness”. (A) Histogram of Lipinski violations as a percentage of the
CamMedNP data set. (B, C, D, E, F) Distribution curves of the NRB, MW, log P, HBA and HBD respectively for the 1,859 compounds currently in
CamMedNP. For subfigure C, the x-axis label is the lower limit of binned data, e.g. 0 is equivalent to 0 to 100.
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Figure 4 Pairwise comparison of mutual relationships between molecular descriptors. (A) The distribution of the calculated log P versus
MW and (B) NRB versus MW.
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http://www.biomedcentral.com/1472-6882/13/88against Chlorella fusca, etc. against Bacillus subtilis ATCC
6633, activity against gram-positive Bacillus megaterium,
etc., cytotoxic activity against the HT-29 and HCT 116
human colon cancer cell lines, against colorectal human
cancer cells, against human promyelocytic leukemia (HL-
60), human hepato-cellular carcinoma and against the hu-
man Caucasian prostate adenocarcinoma cell line PC-3,
enhancement of cAMP-regulated chloride conductance of
cells expressing CFTRΔF508, human neutrophil respira-
tory burst inhibition, and estrogenic activities. For the ma-
jority of cases, antiplasmodial activity was measured byFigure 5 Comparison of property distribution for the CamMedNP and
partition coefficient, (C) hydrogen bond acceptors and (D) hydrogen bond
the x-axis label is the lower limit of binned data, e.g. -2 is equivalent to −2inhibition of the chloroquine-resistant W2 P. falciparum
strain with IC50 < 5 μM. Cytotoxicity measurements were
carried out in potato disk tumor induction assay and some
compounds showed interesting inhibitory properties
against human DU-145 and hepatocarcinoma Hep G2
cells with >70% inhibition at 50 μg/mL. Anti-salmonellal
assays were measured by minimum inhibitory concentra-
tion (MIC) and minimum bactericidal concentration
(MBC) values of respectively in μg/mL against Salmonella
typhi, S. paratyphi A and S. paratyphi B, and most com-
pounds showed < MBC values of 100 μg/mL. Full detailsDNP data sets. (A) molar weight, (B) logarithm of octan-1-ol/water
donors. DNP in white and CamMedNP in black. For subfigure B,
to −1.
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cited references within the database.
Utility and discussion
Discussion of Lipinski’ “drug-likeness” criteria
Nowadays, the identification of lead compounds often
involves the development of compound libraries with a
high level of molecular diversity within the limits of signifi-
cant “drug-like” properties. On these grounds, Lipinski’s
criteria [27] have been used in the evaluation of the “drug-
likeness” of the compounds within the CamMedNP data-
base. The distributions of the compound molecular
weights (MW), lipophilicity (log P), number of hydrogen
bond acceptors (HBA), number of hydrogen bond donors
(HBD) were calculated and used to compare the “drug-
likeness” of CamMedNP with 126,140 compounds from
the Dictionary of Natural Products (DNP) [28], previously
analyzed, and retrieved from the literature [5]. It is note-
worthy that natural products exhibit a wide range of flexi-
bility, from rigid conformationally constrained molecules
to very flexible compounds. Thus, the number of rotatable
bonds (NRB) within the CamMedNP library was used asFigure 6 A simple descriptor-based comparison of the CamMedNP da
typical physicochemical property distributions (MW, HBA, HBD, NN, NO, NR
Diverset (red) database. All histograms and scatterplots were generated witan additional criterion to test for the favourable drug me-
tabolism and pharmacokinetics (DMPK) outcomes. It was
observed that 54.6% of the compounds within CamMedNP
showed no Lipinski violations and 78.7% showed < 2 viola-
tions (Figure 3A), while the peak of the distribution of the
NRB was between 1 and 2 (Figure 3B). Moreover, the ana-
lysis of the distributions of MW showed a peak value be-
tween 301 and 400 Da (Figure 3C), with a curve similar to
those previously reported for other “drug-like” NP libraries
in the literature [5,29] and about 22% of MW > 500 Da.
The distribution of the log P values showed a Gaussian
shaped curve with a peak centred at 3.5 log P units
(Figure 3D). However, some of the compounds had excep-
tionally large log P values, which went up to > 22 units.
This may be explained by the fact that the training data-
base/algorithm used to calculate log P may not suit the
types and combinations of functional groups found in
natural products [5]. It should however be noted that,
inspite of this limitation, 73.1% of the compounds from
CamMedNP had log P values < 5 units. The peaks of
the HBA and HBD were respectively at 5 acceptors and
2 donors and both curves fell off rapidly to maximumtabase and the Chembridge Diversity database. Comparison of
B, log P, NR and TPSA) in the CamMedNP (green) and ChemBridge
h the R software [30].
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also noted that only 8.6% of the compounds in
CamMedNP had HBA > 10 and only about 9.4% had
HBD > 5. Additionally, the pairwise comparison displaying
the mutual relationship between the molecular weight ver-
sus the calculated log P and the number of rotatable
bonds are specified in Figures 4A and 4B, respectively.
The plots show that the regions with the highest popula-
tion densities fall within the “Lipinski region of interest”
(MW < 500, -2 < log P < 5), and for which NRB < 5.
Comparison with the dictionary of natural products
A comparison of the distributions for the individual pa-
rameters for CamMedNP and the DNP is shown in
Figure 5. In these histograms, we show only data that falls
within the “Lipinski region of interest” (MW < 500, -2 <
log P < 5, HBA < 10, and HBD < 5), and the values are
expressed as a percentage count of their respective data-
bases. In all cases the distributions of CamMedNP were
enhanced for the Lipinski properties (peaks of the distri-
butions moved to more “drug-like” properties) when com-
pared to the DNP. The MW distribution (Figure 5A)
peaks at 301–400 Da for both the DNP and the
CamMedNP. The percentage of MW in the range 301–Figure 7 A principal component analysis (PCA) plot, showing the com
(green) and the chemical space represented by NPs in the ChemBridg500 is significantly higher for CamMedNP. Below this
range the percentages were reduced for the CamMedNP
when compared to the DNP.
This improved profile for MW is exactly what is
desirable for a more “drug-like” library, according to
Lipinski’s criteria. The proportions of the two databases
that satisfy Lipinski’s MW property (<500 Da) were 73%
for DNP and 78% for CamMedNP. The distribution
maxima for calculated log P (Figure 5B) were similar for
both databases, with CamMedNP appearing between log
P values of 3–4 and DNP giving a value between 2 and
3. A similar trend was observed for the MW distribu-
tion. This showed an enhancement of 11.2% for MW
values between 301 and 500 Da of CamMedNP over the
DNP and a corresponding 13.1% enhancement for log P
values between 2 and 5 units. For HBA and HBD re-
spectively (Figures 5C-D), CamMedNP showed improve-
ments of 18.7% for 3 < HBA < 8 and 10.3 % for 0 <
HBD < 4 over the DNP. The peak of the distribution for
the HBA for the CamMedNP is at 5 acceptors (18.5%)
with a significant increase in 6 or 7 acceptors when
compared to the DNP (Figure 5C). Similarly, the peak of
the distribution for the HBD for the CamMedNP is at 2
acceptors (24.5%) with a significant increase in 1 or 2parison of the chemical space defined by the NPs in CamMedNP
e Diversity (red) databases.
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summary of the four Lipinski parameters for the two da-
tabases, thus reveals that the CamMedNP library is more
“drug-like” than the DNP. This is an indication that the
chances of finding “lead-like” molecules with improved
DMPK properties within a library such as CamMedNP
are quite significant. The descriptors useful in ADMET
prediction will also be included in the searchable version
of the CamMedNP database.
Diversity analysis
In general, a diverse set of compounds should maximise
the coverage of biological activity and minimise redun-
dancy. The diversity of the CamMedNP database was
analysed in comparison with a relatively large and diverse
compound collection, namely the DIVERSet™ Database
(48,651 compounds) from the ChemBridge Corporation
[26]. A simple descriptor-based comparison of the
CamMedNP database and the Chembridge Diversity data-
base was carried out. The calculated descriptors include
MW, HBA, HBD, log P, NR, NRB, NN, NO, NRB and
TPSA (Figure 6). The regions of the histograms which are
shown in dark green represent regions of intersection,
while those of CamMedNP are shown in light green and
those of ChemBridge in red. While the MW of the
ChemBridge database is restricted to the range 200 ≤ MW
≤ 500 Da, that of CamMedNP stretches well beyond 1000
Da, an observations which could be explained by the com-
plexity and large sizes of some of the NPs in CamMedNP.
This remark could also explain the trend which is seen for
the stretch in the distributions of log P, HBD, NO, NRB,
NR, TPSA and HBA for CamMedNP, when compared with
the ChemBridge dataset. On the contrary, the distribution
of nitrogens for the ChemBridge database has a wider ex-
tent than that of CamMedNP. The overall results show that
the CamMedNP database covers another physicochemical
space than the ChemBridge Diversity database. The princi-
pal component analysis (PCA) scatter plot of the previously
calculated physicochemical properties of the CamMedNP
(green) and ChemBridge Diverset database (red) is shown
in Figure 7. The first three principal components (PCs)
explain 83% (CamMedNP) and 64% (ChemBridge) of the
variance of the individual databases. The larger number of
outliers in the case of the CamMedNP database indicates a
wider sampling of the chemical space compared to the
ChemBridge Diverset collection.
Usefulness of the CamMedNP library
The usefulness of the CamMedNP database in lead gen-
eration has been exemplified with the docking and
pharmacophore-based screening for potential inhibitors
of a validated anti-malarial drug target in our laboratory,
and the results will be published in a subsequent paper.
CamMedNP is constantly being updated; meanwhile acomputer program to facilitate the searching of this
database is under development and will also be pub-
lished subsequently. However, 3D structures of the com-
pounds, as well as their physico-chemical properties that
were used to evaluate “drug-likeness”, can be freely
downloaded as a supplementary file accompanying this
publication. In addition, information about compound
sample availability can be obtained on request from the
authors of this paper or from the pan-African Natural
Products Library (p-ANAPL) project [31,32].
Conclusions
Virtual screening workflows usually involve docking a
compound library into the binding site of a target recep-
tor and using scoring functions and binding free energy
calculations to identify putative binders. The availability
of 3D structures of the compounds to be used for
docking is of utmost importance. Therefore the availabil-
ity of such structures within CamMedNP, as well as their
calculated physico-chemical properties and indicators of
“drug-likeness” within this newly developed database will
facilitate the drug discovery process from leads that have
been identified from Cameroonian medicinal plants.
Availability and requirements
3D structures of the compounds, as well as their physico-
chemical properties that were used to evaluate “drug-
likeness”, can be freely downloaded (for non commercial
uses) as a supplementary file accompanying this publica-
tion (Additional file 2). Physical samples for testing are
available at the various research labs in Cameroon in vary-
ing quantities. Questions regarding the available of com-
pound samples could be addressed directly to the authors
of this paper. Otherwise samples could be obtainable from
the p-ANAPL consortium, which has a mandate to collect
samples of NPs from the entire continent of Africa and
make them available for biological screening. This network
is being set up under the auspices of the Network for Ana-
lytical and Bioassay Services in Africa (NABSA) [31,32].
Additional files
Additional file 1: Full list of consulted journals in constructing
CamMedNP.
Additional file 2: 3D structures of compounds currently included in
CamMedNP. This file is saved in .mdb format (which can be viewed using
MOE) and could be converted into .sdf, .mol, or .mol2 (using the software
MOE) or into .ldb format using the software LigandScout.
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